Dr. Reddy’s Laboratories (DRREDDY) Q3 24/25 earnings summary

Executive summary

• Achieved double-digit revenue growth of 16% year-over-year and 4% sequentially, with EBITDA margin at 27.5% and ROCE at 28%.

• First quarter of consolidation for the acquired NRT business, contributing significantly to revenue and EBITDA, especially in Europe.

• Continued investment in R&D, innovation, and commercial capabilities, focusing on generics, consumer healthcare, innovative products, and biosimilars.

• Launched new products in immuno-oncology and chronic constipation in India, and secured biosimilar approvals in the UK.

• Maintained strong ESG performance, ranking fifth globally among pharma companies in S&P Global CSA and upgraded MSCI ESG rating to 'A'.

Financial highlights

• Q3FY25 consolidated revenue was ₹83.6 billion (INR 8,359 crores/$977 million), up 16% year-over-year and 4% sequentially.

• Excluding NRT, underlying revenue growth was 7.5% year-over-year and declined 3% sequentially.

• Q3FY25 gross profit was ₹49.1 billion (58.7% margin), up 16% year-over-year; EBITDA at ₹23.0 billion (27.5% margin), up 9% year-over-year.

• Net profit after tax was ₹14.1 billion (INR 1,413 crores/$165 million), up 2% year-over-year and 13% sequentially; EPS at ₹16.94.

• Net cash surplus as of December 31, 2024, was ₹16.0 billion (INR 1,603 crores/$187 million); net debt/equity: (0.05).

Outlook and guidance

• R&D investment expected to be 8.5%-9% of sales for the full fiscal year.

• Normalized effective tax rate projected around 25%.

• SG&A expenses expected to remain around 28% of sales.

• Focus on integrating NRT business and driving growth in consumer healthcare, innovative products, and biosimilars.

• Ongoing investments in R&D and expansion in key markets are anticipated to support future growth.